Turkey Emerging As Favored Destination For Cancer Drugs Clinical Trials Says Kuick Research In New Study
Delhi, Sept. 10, 2024 (GLOBE NEWSWIRE) — Turkey Cancer Drugs Clinical Trials Insight 2024 Report Offering:
-
Turkey Clinical Trials Market Opportunity 2024 and 2030 (In US$ Million)
-
Clinical Trials Regulatory Framework In Turkey
-
Total Number of Cancer Drugs In Clinical Trials In Turkey
-
Total Number Of Cancer Drugs Approved In Turkey
-
300 Pages Clinical Trials Insight on All Cancer Drugs In Clinical Trials By Company, Indication and Phase
-
50 Pages Clinical Insight On All Cancer Drugs Approved in Market By Company and Indication
-
Insight On 18 Pharmaceutical Companies and 5 CRO
Download Report:
https://www.kuickresearch.com/report-turkey-cancer-drugs-clinical-trials
Turkey has become an increasingly attractive destination for clinical trials, driven by a growing healthcare sector, strategic location between Europe and Asia, and an evolving regulatory environment. The country’s diverse population, modern infrastructure, and competitive costs have made it a focal point for both local and international pharmaceutical companies seeking to conduct clinical trials. Over the past decade, Turkey has made considerable progress in expanding its clinical trial capabilities, although challenges remain in fully realizing its potential.
One of Turkey’s significant advantages in the clinical trial sector is its large and diverse population. With more than 80 million people, the country offers a vast pool of potential trial participants, which is critical for conducting robust, large-scale clinical trials. Additionally, the demographic diversity in Turkey provides pharmaceutical companies with the opportunity to test drugs across different genetic backgrounds and ethnic groups, improving the generalizability of clinical trial results. This makes Turkey a valuable location for trials intended for global markets.
Turkey’s healthcare infrastructure has seen substantial improvements, with numerous hospitals and research centers equipped to handle complex clinical trials. The country boasts a network of both public and private healthcare institutions that are increasingly participating in clinical research. Many hospitals are internationally accredited, ensuring that clinical trials meet global standards in terms of quality and safety. The modernization of healthcare facilities, coupled with a well-trained workforce of medical professionals, has further bolstered Turkey’s attractiveness for clinical trials.
In recent years, the Turkish government has also shown a strong commitment to fostering a favorable environment for clinical research. The Ministry of Health has introduced several initiatives to simplify the clinical trial approval process and reduce bureaucratic hurdles. The Turkish Medicines and Medical Devices Agency (TITCK) is responsible for overseeing clinical trials, and recent regulatory reforms have aimed at shortening approval times, making Turkey more competitive with other countries in the region. Despite these improvements, approval times are still somewhat lengthy compared to those in Western Europe or North America, and further streamlining will be essential to attract more international trials.
Turkey has seen growth in clinical trials across a variety of therapeutic areas, particularly in oncology, cardiology, and neurology. The country has become a hub for oncology research, driven by the increasing incidence of cancer in the region and the availability of well-equipped cancer treatment centers. Clinical trials for rare diseases and immunotherapies are also on the rise, reflecting global trends in medical research. Turkey’s participation in global clinical trials during the COVID-19 pandemic further demonstrated its capability to handle high-profile, large-scale trials under demanding conditions.
However, several challenges continue to hinder the full realization of Turkey’s potential in clinical trials. One of the key issues is the limited local funding for clinical research. While international pharmaceutical companies are active in funding trials in Turkey, local innovation often struggles due to a lack of financial support. This has led to a reliance on foreign investments and expertise for the majority of clinical trials conducted in the country.
Furthermore, Turkey faces challenges in terms of patient recruitment and retention. Although the country has a large population, cultural factors and public awareness about clinical trials can sometimes limit patient participation. Increasing efforts to educate the public about the importance of clinical trials and ensuring that participants are adequately informed about their role in medical research will be critical to overcoming these challenges.
In conclusion, Turkey is emerging as a key player in the global clinical trial landscape, thanks to its large and diverse population, improving healthcare infrastructure, and regulatory reforms. The country has demonstrated its capacity to handle complex trials, particularly in areas like oncology and rare diseases. However, addressing challenges such as regulatory bottlenecks, limited local funding, and patient recruitment will be crucial to further enhancing Turkey’s standing as a clinical trial hub. As the country continues to invest in its healthcare sector and refine its regulatory processes, Turkey is well-positioned to play an increasingly significant role in the global clinical trials market.
CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@kuickresearch.com https://kuickresearch.com
